Trial Profile
Phase II Study of Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Nimustine
- Indications Glioblastoma
- Focus Therapeutic Use
- 14 Jul 2018 Status changed from active, no longer recruiting to completed.
- 06 May 2018 Planned number of patients changed from 40 to 24.
- 06 May 2018 Planned End Date changed from 1 Feb 2017 to 15 May 2018.